1. Home
  2. SNAP vs RPRX Comparison

SNAP vs RPRX Comparison

Compare SNAP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNAP
  • RPRX
  • Stock Information
  • Founded
  • SNAP 2010
  • RPRX 1996
  • Country
  • SNAP United States
  • RPRX United States
  • Employees
  • SNAP N/A
  • RPRX N/A
  • Industry
  • SNAP Computer Software: Programming Data Processing
  • RPRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNAP Technology
  • RPRX Health Care
  • Exchange
  • SNAP Nasdaq
  • RPRX Nasdaq
  • Market Cap
  • SNAP 16.3B
  • RPRX 14.2B
  • IPO Year
  • SNAP 2017
  • RPRX 2020
  • Fundamental
  • Price
  • SNAP $8.89
  • RPRX $31.37
  • Analyst Decision
  • SNAP Hold
  • RPRX Strong Buy
  • Analyst Count
  • SNAP 32
  • RPRX 5
  • Target Price
  • SNAP $13.85
  • RPRX $41.60
  • AVG Volume (30 Days)
  • SNAP 27.7M
  • RPRX 4.2M
  • Earning Date
  • SNAP 04-24-2025
  • RPRX 05-08-2025
  • Dividend Yield
  • SNAP N/A
  • RPRX 2.81%
  • EPS Growth
  • SNAP N/A
  • RPRX N/A
  • EPS
  • SNAP N/A
  • RPRX 1.91
  • Revenue
  • SNAP $5,361,398,000.00
  • RPRX $2,263,576,000.00
  • Revenue This Year
  • SNAP $15.92
  • RPRX $33.46
  • Revenue Next Year
  • SNAP $12.87
  • RPRX $4.44
  • P/E Ratio
  • SNAP N/A
  • RPRX $16.41
  • Revenue Growth
  • SNAP 16.40
  • RPRX N/A
  • 52 Week Low
  • SNAP $8.29
  • RPRX $24.05
  • 52 Week High
  • SNAP $17.33
  • RPRX $34.20
  • Technical
  • Relative Strength Index (RSI)
  • SNAP 39.56
  • RPRX 35.44
  • Support Level
  • SNAP $8.34
  • RPRX $32.26
  • Resistance Level
  • SNAP $9.70
  • RPRX $34.14
  • Average True Range (ATR)
  • SNAP 0.37
  • RPRX 0.76
  • MACD
  • SNAP 0.07
  • RPRX -0.29
  • Stochastic Oscillator
  • SNAP 40.07
  • RPRX 11.78

About SNAP Snap Inc.

Snap is a technology company best known for its marquis social media application Snapchat, a visual messaging application that has amassed hundreds of millions of users. The app was initially only used to communicate with family and friends through photographs and short videos (known as "Snaps"). Users can now enjoy augmented reality, or AR, lenses, content from famous creators and celebrities, updates about local events, and more. Although the app offers a paid subscription option with premium features, advertising sales produce most of the app's revenue. The firm also sells wearable devices called AR Spectacles, which can capture photos and videos overlayed with AR lenses, but these make up a small portion of Snap's overall sales.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: